These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 28146201)

  • 21. Challenges in estimating the impact of pneumococcal conjugate vaccines through surveillance.
    Vergison A; Hanquet G
    Pediatr Infect Dis J; 2012 Apr; 31(4):400-3. PubMed ID: 22418653
    [No Abstract]   [Full Text] [Related]  

  • 22. Prevention of pneumococcal disease in children. Pneumococcal conjugate vaccines: their use globally could have a major impact on public health.
    Kyaw MH; Jones IG; Campbell H
    Acta Paediatr; 2001 May; 90(5):473-6. PubMed ID: 11430703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pneumococcal vaccination for Indian children.
    Levine OS; Cherian T
    Indian Pediatr; 2007 Jul; 44(7):491-6. PubMed ID: 17684301
    [No Abstract]   [Full Text] [Related]  

  • 24. An update on the new pneumococcal conjugate vaccine.
    Holland MJ
    Pediatr Ann; 2001 Sep; 30(9):515-6. PubMed ID: 11554259
    [No Abstract]   [Full Text] [Related]  

  • 25. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections.
    Zangeneh TT; Baracco G; Al-Tawfiq JA
    Expert Rev Vaccines; 2011 Mar; 10(3):345-53. PubMed ID: 21434802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of pneumococcal polysaccharide vaccine on nonbacteremic pneumococcal pneumonia.
    Weiser JN; Austrian R
    Clin Infect Dis; 2007 Apr; 44(8):1139-40; author reply 1140-1. PubMed ID: 17366469
    [No Abstract]   [Full Text] [Related]  

  • 27. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children.
    Thanee C; Pancharoen C; Likitnukul S; Luangwedchakarn V; Umrod P; Phasomsap C; Apornpong T; Chuanchareon T; Butterworth O; Puthanakit T
    Vaccine; 2011 Aug; 29(35):5886-91. PubMed ID: 21729732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Letter from the Editor: pneumococcal conjugate vaccine.
    Ellis R
    Hum Vaccin Immunother; 2014; 10(9):2754. PubMed ID: 25483629
    [No Abstract]   [Full Text] [Related]  

  • 29. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development.
    Reinert R; Jacobs MR; Kaplan SL
    Vaccine; 2010 Jun; 28(26):4249-59. PubMed ID: 20416266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New insights on pneumococcal disease: what we have learned over the past decade.
    Dagan R
    Vaccine; 2009 Aug; 27 Suppl 3():C3-5. PubMed ID: 19552985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A 10-valent conjugate vaccine for some countries.
    Prescrire Int; 2011 Jan; 20(112):8. PubMed ID: 21462783
    [No Abstract]   [Full Text] [Related]  

  • 32. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
    Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R
    Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pneumococcal conjugate vaccine introduction in Latin America and the Caribbean: progress and lessons learned.
    de Oliveira LH; Trumbo SP; Ruiz Matus C; Sanwogou NJ; Toscano CM
    Expert Rev Vaccines; 2016 Oct; 15(10):1295-304. PubMed ID: 26982434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Laboratory surveillance of invasive pneumococcal disease in Australia, 2003 predicting the future impact of the universal childhood conjugate vaccine program.
    Watson M; Roche P; Bayley K; Bell JM; Collignon P; Gilbert GL; Hogg G; Keil AD; Krause V; Murphy D; Smith HV; Brown M; Stylianopoulos J; Turnidge J
    Commun Dis Intell Q Rep; 2004; 28(4):455-64. PubMed ID: 15745392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PCV7-induced changes in pneumococcal carriage and invasive disease burden in Alaskan children.
    Keck JW; Wenger JD; Bruden DL; Rudolph KM; Hurlburt DA; Hennessy TW; Bruce MG
    Vaccine; 2014 Nov; 32(48):6478-84. PubMed ID: 25269095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pediatric hospitalization for pneumococcal diseases preventable by 7-valent pneumococcal conjugate vaccine in Hong Kong.
    Ho PL; Chiu SS; Chow FK; Mak GC; Lau YL
    Vaccine; 2007 Sep; 25(39-40):6837-41. PubMed ID: 17714837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
    Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
    Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine.
    Sharma D; Baughman W; Holst A; Thomas S; Jackson D; da Gloria Carvalho M; Beall B; Satola S; Jerris R; Jain S; Farley MM; Nuorti JP
    Pediatr Infect Dis J; 2013 Feb; 32(2):e45-53. PubMed ID: 23080290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England.
    van Hoek AJ; Sheppard CL; Andrews NJ; Waight PA; Slack MP; Harrison TG; Ladhani SN; Miller E
    Vaccine; 2014 Jul; 32(34):4349-55. PubMed ID: 24657717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.